United Therapeutics | UTHR - Assets


United Therapeutics reported $6.71B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Amarin USD 645.76M 25.01M Mar/2026
Ardelyx USD 504.51M 2.9M Mar/2026
Baxter International USD 19.85B 209M Mar/2026
Bayer EUR 107.94B 3.4B Mar/2026
BioCryst Pharmaceuticals USD 465.05M 49.11M Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Emergent BioSolutions USD 1.82B 69.9M Dec/2023
Esperion Therapeutics USD 462.53M 3.36M Mar/2026
Gilead Sciences USD 56.28B 2.74B Mar/2026
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
Halozyme Therapeutics USD 2.67B 147.4M Mar/2026
Insmed USD 2.08B 188.7M Mar/2026
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
J&J USD 200.89B 1.68B Mar/2026
Lexicon Pharmaceuticals USD 268.82M 83.83M Mar/2026
Moderna USD 11.49B 850M Mar/2026
Omeros USD 200.57M 34.59M Jun/2025
Pfizer USD 207.62B 542M Mar/2026
PTC Therapeutics USD 2.87B 29.66M Mar/2026
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
Teva Pharmaceutical Industries USD 40.04B 708M Mar/2026
United Therapeutics USD 6.71B 1.17B Mar/2026
Vertex Pharmaceuticals USD 26.48B 841.4M Mar/2026